Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,577.77
(
-0.71%
)
US TECH 100
23,586.00
(
-0.88%
)
Dow Jones
45,828.68
(
-0.86%
)
Brent Oil
105.59
(
-0.93%
)
Bitcoin
69,798.79
(
-2.03%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 75491

Saturday, 04/04/2009 3:44:51 PM

Saturday, April 04, 2009 3:44:51 PM

Post# of 257259

Clevudine's different MoA makes it a good candidate for combo therapy, should it be adopted in HBV.

I think VRUS’ claim that Clevudine has “a different MoA” from other HBV nukes is partly spin. The more relevant impetus for combination therapy including Clevudine, IMO, is the comment in the bottom paragraph of #msg-36811361.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now